U.S. downturn could hurt AIDS vaccine drive: group

By Wendell Roelf

CAPE TOWN (Reuters) - A U.S. recession could cut AIDS funding and impede the drive to find a vaccine for the disease, a senior official with a group spearheading vaccine research said on Tuesday.

The United States is the center of AIDS vaccine research. Its government contributed $659 million, or 69 percent of the funds earmarked for research in 2007, according to data released at a global AIDS vaccine conference in Cape Town.

But a credit crunch has raised fears that the world’s richest economy could be headed for recession, prompting the U.S. government and private sector to cut funding to a broad range of programs, including AIDS research.

“If there is a downturn in the economy it’s going to potentially have a negative impact on funding for science in general and HIV vaccine research in particular,” Alan Bernstein, executive director of the Global HIV Vaccine Enterprise, told Reuters at the conference.

The conference — a gathering of many of the top names in HIV research — follows a year that saw scientists drop plans for widespread human testing of the two most promising vaccine prototypes due to safety concerns.

The AIDS virus infects an estimated 33 million people globally and has killed between 23 and 25 million since it was identified in the 1980s. Cocktails of anti-retroviral drugs can control the virus, but there is no cure.

The two stalled vaccines, one developed by drug giant Merck and the other by U.S. government researchers, both aimed to fight AIDS by jump-starting T-cells to tackle the virus and stop or slow the progress of HIV-related disease.

Early results from a large human trial of the Merck product were discouraging, and data showed the vaccine may have left some people more prone to HIV infection — halting the tests and prompting some scientists to reconsider the model.  Continued…


Related Posts:

By Andrew Quinn WASHINGTON (Reuters) - A global AIDS vaccine conference this week will seek fresh strategies against the HIV virus, with experts weighing the value of basic laboratory research against large-scale human clinical trials after a string of disappointments. Approaches focusing on “neutralizing antibodies” that would allow the human immune system to block infection completely, are

Full Post: AIDS vaccine focus shifts after disappointments

By Laura MacInnis GENEVA (Reuters) - The body’s initial response to contracting HIV could provide the answers scientists need to develop a vaccine for the AIDS-causing virus, a Nobel-winning expert said on Monday. The AIDS epidemic has killed about 25 million people, and about 33 million worldwide are now infected with HIV. Cocktails of drugs can control

Full Post: First days after HIV infection may hold vaccine key

By Adam Cox STOCKHOLM (Reuters) - A French scientist who shared this year’s Nobel prize for medicine said on Saturday he believed the transmission of AIDS could be eliminated within years. Luc Montagnier, director of the World Foundation for AIDS Research and Prevention, told a news conference together with this year’s other winners for medicine that halting

Full Post: Nobel winner sees end to AIDS spread within years

By Will Dunham WASHINGTON (Reuters) - A quarter of girls aged 13-17 in the United States received Merck & Co’s Gardasil vaccine last year to protect against the human papillomavirus, which causes cervical cancer, the U.S. government said on Thursday. A report by the Centers for Disease Control and Prevention provided the first look at how many

Full Post: Quarter of adolescent U.S. girls received HPV vaccine

LONDON (Reuters) - Top-selling author Terry Pratchett will deliver a petition to British Prime Minister Gordon Brown on Wednesday calling for an urgent increase in funding for dementia research. Pratchett, 60, creator of the “Discworld” series, revealed last December he had been diagnosed with a rare form of early-onset Alzheimer’s disease. “I am appalled that research into

Full Post: Author Terry Pratchett in UK Alzheimer’s plea

Site Navigation

Most Read



  • kinwrite.com@gmail.com